Technical Analysis for UTHR - United Therapeutics Corporation

Grade Last Price % Change Price Change
grade C 118.65 -0.17% -0.20
UTHR closed down 0.17 percent on Tuesday, March 19, 2019, on 78 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Flat Up Up
See historical UTHR trend table...

Date Alert Name Type % Chg
Mar 19 MACD Bullish Signal Line Cross Bullish 0.00%
Mar 19 Calm After Storm Range Contraction 0.00%
Mar 19 Multiple of Ten Bearish Other 0.00%
Mar 18 20 DMA Support Bullish -0.17%
Mar 18 50 DMA Support Bullish -0.17%
Mar 18 Crossed Above 200 DMA Bullish -0.17%
Mar 18 Calm After Storm Range Contraction -0.17%
Mar 18 Outside Day Range Expansion -0.17%
Mar 18 Up 3 Days in a Row Strength -0.17%
Mar 18 Up 4 Days in a Row Strength -0.17%

Older signals for UTHR ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product is Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops oral treprostinil, an orally delivered prostacyclin analog for treatment of pulmonary hypertension; Ch14.18 MAb, an antibody in Phase III clinical trials for the treatment of neuroblastoma; Beraprost 314d, which is entering Phase III clinical trails for the treatment of PAH; PLacental eXpanded cells, which are entering a Phase I trial for the treatment of PAH; and 8H9 MAb, an antibody that is under Phase I clinical trial for the treatment of metastatic brain cancer. Further, the company is involved in the pre-clinical stage of developing TransCon Treprostinil, TransCon Beraprost, and glycobiological antiviral agents for the treatment of infectious diseases, such as Hepatitis C; and engineered lungs and lung tissue, which can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Chemistry Biotechnology Chemical Compounds Infectious Diseases Organic Compounds Alcohols Pulmonary Arterial Hypertension Neuroblastoma Hepatitis C Pulmonary Hypertension Treprostinil Cac All Share Index Chronic And Life Threatening Conditions Oral Therapy Prostaglandins
Is UTHR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 130.0
52 Week Low 100.06
Average Volume 337,993
200-Day Moving Average 118.1139
50-Day Moving Average 116.525
20-Day Moving Average 117.656
10-Day Moving Average 114.39
Average True Range 3.1219
ADX 16.85
+DI 29.4501
-DI 22.1778
Chandelier Exit (Long, 3 ATRs ) 119.5743
Chandelier Exit (Short, 3 ATRs ) 118.7557
Upper Bollinger Band 127.3738
Lower Bollinger Band 107.9382
Percent B (%b) 0.55
BandWidth 16.519005
MACD Line -0.0661
MACD Signal Line -0.1816
MACD Histogram 0.1156
Fundamentals Value
Market Cap 5.16 Billion
Num Shares 43.5 Million
EPS 8.62
Price-to-Earnings (P/E) Ratio 13.76
Price-to-Sales 3.17
Price-to-Book 2.91
PEG Ratio -0.38
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 122.14
Resistance 3 (R3) 122.38 121.46 121.56
Resistance 2 (R2) 121.46 120.57 121.34 121.37
Resistance 1 (R1) 120.06 120.02 119.60 119.81 121.17
Pivot Point 119.13 119.13 118.90 119.01 119.13
Support 1 (S1) 117.73 118.25 117.27 117.49 116.13
Support 2 (S2) 116.81 117.70 116.69 115.93
Support 3 (S3) 115.40 116.81 115.74
Support 4 (S4) 115.16